CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
There are several ASX ETFs designed to track the S&P/ASX 200 (INDEXASX: XJO) but only one to track the top 50 companies on the ASX. How does the SPDR S&P/ASX 50 Fund (ASX: SFY) compare?
The iShares Edge MSCI Australia Multifactor ETF (ASX: AUMF) is coming up on three years listed on the ASX. Here’s a review of how it has performed and what the outlook could be.
I think CSL Limited (ASX:CSL) shares would be up there as Australia’s best blue-chip growth stock story.
The CSL Limited (ASX:CSL) share price rose by almost 7% today after it reported its FY19 result.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.12% at lunch.
The ASX 200 (INDEXASX:XJO)(^AXJO) is expected to open higher today, the USA’s S&P 500 Index (.INX) rose by 1.48% on Tuesday.
The CSL Limited (ASX:CSL) share price could be one of today’s movers after reporting its FY19 result and providing guidance for FY20.
CSL Limited (ASX:CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals.
A decade after the last high, the ASX 200 (INDEXASX:XJO)(^AXJO) has finally topped its previous all time high.
